Compare STEP & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEP | MMED |
|---|---|---|
| Founded | 2007 | 1983 |
| Country | United States | United States |
| Employees | N/A | 2800 |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.3B |
| IPO Year | 2020 | 2026 |
| Metric | STEP | MMED |
|---|---|---|
| Price | $43.20 | $17.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $71.00 | $22.56 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 05-21-2026 | 06-03-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,993,603,000.00 | N/A |
| Revenue This Year | N/A | $15.99 |
| Revenue Next Year | $26.41 | $10.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 69.69 | N/A |
| 52 Week Low | $38.85 | $10.65 |
| 52 Week High | $77.80 | $17.86 |
| Indicator | STEP | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 68.09 |
| Support Level | $41.11 | $14.70 |
| Resistance Level | $49.24 | N/A |
| Average True Range (ATR) | 2.11 | 0.87 |
| MACD | 0.41 | 0.12 |
| Stochastic Oscillator | 55.97 | 93.49 |
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.